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In an effort to quantitate Py–Im polyamide concentrations in vivo, we synthesized the C-14 radioactively
labeled compounds 1–3, and investigated their tumor localization in a subcutaneous xenograft model of
prostate cancer (LNCaP). Tumor concentrations were compared with representative host tissues, and
exhibited a certain degree of preferential localization to the xenograft. Compound accumulation upon
repeated administration was measured. Py–Im polyamide 1 was found to accumulate in LNCaP tumors
at concentrations similar to the IC50 value for this compound in cell culture experiments.
 2014 Published by Elsevier Ltd.1. Introduction MS quantitation methods. Consequentially, this technique wasPy–Im polyamides are a modular class of organic molecules,
which can be programmed to recognize deﬁned DNA sequences
with afﬁnities and speciﬁcities comparable to those of DNA binding
proteins.1 Focused molecular tuning identiﬁed positive determi-
nants of cellular uptake for Py–Im polyamides.2 Ensuing gene reg-
ulation studies demonstrated the potential of these molecules to
occlude binding of various transcription factors, such as the andro-
gen receptor,3 the hypoxia inducible factor,4 and the nuclear factor
kappa-B.5 Importantly, the mode of action of Py–Im polyamides is
not limited to the transcription factor DNA interface. Recent
in vitro studies established that Py–Im polyamides can induce inhi-
bition of the RNA polymerase II activity with subsequent degrada-
tion of the protein, as well as p53 stress response induction,
without accompanying DNA damage.6 We were able to demon-
strate that Py–Im polyamides are bioavailable following an intra-
venous,7 intraperitoneal or a subcutaneous injection,8 and are
taken up by tumors in vivo.9 Subsequent investigations established
their antitumor effects in an LNCaP tumor xenograft model.6,10 This
provided an incentive to develop an approach to quantitate com-
pound levels in tumor xenografts, and to compare those with rep-
resentative tissues of the animal host in vivo.11
Radioactive C-14 labeling allows to synthesize traceable organic
molecules without altering their chemical properties. The
approach enables the observation of in vivo compound uptake
for a relatively prolonged period of time with a wider range of
concentrations, as opposed to the more commonly used LC/MS/put to advantage in investigating biodistribution and metabolism
of diverse molecular classes, comprising small molecules,12 pro-
teins,13 and antibody–drug conjugates.14 The present account
reports the synthesis and biodistribution of three C-14 labeled
Py–Im polyamides in an in vivo tumor xenograft model.
2. Results
2.1. Py–Im polyamide 1 exhibits preferential xenograft
localization
The radioactive, C-14 labeled, eight-ring hairpin Py–Im poly-
amide 1 (ImPyPyPy-(R)a-NHAcc-ImPyPyPy) that codes for the
DNA sequence 50-WGWWCW-30 was of particular interest for
the investigation (Fig. 1). This stems from its recently demon-
strated antitumor activity in a subcutaneous prostate cancer
xenograft model (LNCaP), which was accompanied by reduced
animal toxicity, as compared to closely related molecules.10 An
initial set of single dose experiments was conducted, with tissue
harvest performed 24 h past compound administration. In order
to compare the tumor-associated levels of Py–Im polyamide 1
with its distribution to the animal, host kidney, liver and lung
were chosen as representative organs. A mean tumor-associated
concentration of 1 was measured as 1.48 mg/kg, which corre-
sponds to 1.06 lM (Fig. 2A). Substantially lower concentrations
were observed for kidney and lung (0.25 and 0.12 mg/kg, respec-
tively). The liver displayed a concentration of 1.04 mg/kg of com-
pound 1, which is 29% lower than that established in tumors
(p < 0.01).
Figure 1. Chemical structures and ball-and-stick representations of the C-14
radioactively labeled hairpin Py–Im polyamides 1–3 employed in the study.
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degradation in vivo
To probe for potential metabolic loss of the C-14 radiolabeled
isophthalic acid (IPA) terminus of Py–Im polyamide 1 in vivo, theFigure 2. Compound levels of the C-14 radioactively labeled Py–Im polyamides 1 (A), 2 (
major animal host tissues (kidney, liver and lung). Each datapoint represents an individ
animal (NSG male mouse; N = 10 in each group) and tissues harvested 24 h following adm
comparison was conducted against tumor levels of compounds 1–3.differentially radiolabeled compound 2 was synthesized. The mol-
ecule 2 is chemically identical to 1, but carries the C-14 radioactive
label at the acetate of the a-acetamide-GABA linker unit instead of
the IPA moiety (Fig. 1), thus allowing to probe for compound
decomposition. In both the tumor tissue, as well as for the repre-
sentative host tissues chosen, the corresponding mean values were
determined to be within experimental error between the com-
pounds 1 and 2 (Fig. 2B and Supporting information, Fig. SI1, top
panel).
2.3. In vivo biodistribution of Py–Im polyamide 1 is superior to
analogue 3
Antitumor activity against LNCaP in a subcutaneous xenograft
mouse model was initially demonstrated with the non-radioactive
version of the Py–Im polyamide 3.6 Subsequent studies established
an improved therapeutic index of its acetylated analogue 1.10 The
synthesis and administration of radioactively labeled compound
3 (Fig. 1) for comparison to the biodistribution values measured
for Py–Im polyamide 1 was therefore of high interest (Fig. 2A
and C). Whereas tumor-associated levels were within error
between the two molecules, substantially higher levels of 3 were
noted for all host tissues examined (Supporting information,
Fig. SI1, bottom panel). Particularly striking was the difference in
lung levels, which was almost eightfold higher with 3 (0.12 and
0.93 mg/kg for compounds 1 and 3, respectively).
2.4. In vivo biodistribution of Py–Im polyamide 1 as a function
of post-injection time
In order to gain insight into the uptake and clearance rates of 1
from tumor and the reference host organs chosen, four different
post-injection time points were examined (Fig. 3). The 4 h time
point was chosen to represent the scenario in which compound 1
is still in circulation.10 In addition to the 24 h time point, more pro-
longed exposure time frames were investigated (3 and 7 days,
respectively). At the earliest time point probed, Py–Im polyamide
1 exhibited some twofold enrichment in the tumor over all host
tissues probed. There was no notable difference between the levels
measured for the host kidney, liver and lung, thus pointing towards
a comparable degree of their vascularization and penetration by 1.
Interestingly, a markedly different proﬁle was observed 24 h post-
exposure. Liver values were found to be substantially higher than
those of kidney (4.2-fold) or lung (8.7-fold). Kidney and lung tis-
sues were found to clear Py–Im polyamide 1 at substantially higher
rates than the liver, not much of a change being noted for the latter
between 4 and 24 h (Fig. 3). At prolonged exposure times of up to
7 days, tissue levels of 1were found to diminish consistently, drop-
ping to 0.45 mg/kg (tumor), 0.05 mg/kg (kidney), 0.27 mg/kg (liver)B) and 3 (C) in subcutaneously grafted LNCaP tumors, compared with representative
ual organ analyzed. All injections were performed intraperitoneally at 20 nmol per
inistration. Quantitation was conducted by liquid scintillation counting. Statistical
Figure 3. Compound levels of C-14 labeled Py–Im polyamide 1 in LNCaP tumor and
representative organs at varying post-injection time points. All injections were
performed intraperitoneally at 20 nmol per animal (NSG male mouse; NP 10).
Quantitation was conducted by liquid scintillation counting of the organ harvested
at the indicated time point. Statistical comparison was conducted against tumor
levels of compound 1.
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1 was still readily detectable in all tissues 7 days after its injection
(Figs. 3 and 4).
2.5. Multiple injections of Py–Im polyamide 1 lead to compound
accumulation
Given that our published treatment schedules consist of at least
three injections with compound typically administered every 2–
3 days,9,10 probing for compound accumulation under such condi-
tions was clearly of interest.
A multiple exposure experiment was conducted, following the
treatment schedule displayed in Figure 5. Tissue levels of com-
pound 1 were found to be consistently higher than those observedFigure 4. Compound levels of C-14 labeled Py–Im polyamide 1 in LNCaP tumor and
representative organs, presented in a time-resolved fashion. Compound levels are
compared against their respective levels measured at the 1 day timepoint for all
organs. Repeated injections (rightmost columns) display substantial accumulation.
All injections were performed intraperitoneally at 20 nmol per animal (NSG male
mouse). Quantitation was conducted by liquid scintillation counting. Each data-
point represents an individual organ analyzed. Statistical comparison was con-
ducted against tumor levels of compound 1. R(1;4;7) denotes the accumulation
experiment; see also Figure 5.in single injection experiments. Comparison with the 24 h time
point revealed that 1 accumulated at concentrations ranging from
1.8-fold (liver and kidney) to 2.4-fold (tumor) higher following
three injections. Single injection experiments with longer exposure
time points displayed consistently lower compound levels.
3. Discussion
The C-14 radiolabeling approach represents a sensitive way of
creating readily detectable molecules with an extended tracer life-
time, without altering their chemical properties. The technology
has been highly valuable in investigating medicinally important
small molecules of relevance to the treatment of cancer and other
diseases. Examples encompass the toxin colchicine,15 the antidia-
betic candidate muraglitazar,16 the DNA-binding cytotoxic agent
doxorubicin,17 the camptothecin analogue lurtotecan,18 and the
mitotic inhibitor paclitaxel.19 The quantitative approach using
radiolabeled polyamides allows determining, at least in part, their
pharmacokinetic and pharmacodynamic parameters. A preceding
study from our laboratory employed 18F labeling, which allows
tracing molecules in vivo, employing the non-invasive positron
emission tomography imaging technology.11 An 8-ring hairpin
polyamide coding for the sequence 50-WTWCGW-30 was evaluated,
revealing liver accumulation and GI-effected compound excretion
as some key ﬁndings. However, 18F being a short-lived radionuclide
(t1/2 of 109.8 min), the 18F-labeled compound was only traced for
2 h following injection. In order to shed light onto chemotherapeu-
tic potential of polyamides, substantially more extended time
points are required. This is afforded by employing the 14C labeling
technique, which is the focus of the present study. The ﬁndings can
be correlated with the tumor growth attenuation, as well as animal
toxicity.10 Furthermore, insight can be gained into their mechanis-
tic mode of action in vivo. Both aspects are of high signiﬁcance for
translational research, as discussed below.
A. Chemotherapeutic aspects: An ideal chemotherapeutic in can-
cer therapy should exert its cytotoxic activity at the tumor site
exclusively, without causing damage to any healthy host tissues.
This hypothetical scenario is not achieved with any of the currentlyFigure 5. Compound levels of C-14 labeled Py–Im polyamide 1 in LNCaP tumor and
representative organs following three injections on days 1, 4 and 7 of the
experiment. Compound was administered intraperitoneally at 20 nmol per animal
per injection (NSG male mouse). Harvest was performed 24 h following the last
injection. Quantitation was conducted by liquid scintillation counting. Each
datapoint represents an individual organ analyzed. Statistical comparison was
conducted against tumor levels of compound 1.
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treatment of neoplasias that possess well-characterized genomic
lesions, which are indispensable for tumor proliferation. Notable
improvements in treatment of advanced prostate cancer have been
achieved over the past decade. Novel FDA-approved therapeutics
encompass the aromatase inhibitor abiraterone,20 the inhibitor of
androgen receptor (AR) signaling enzalutamide,21 and radium-
223, which is an alpha-emitting radiopharmaceutical applied in
the treatment of prostate cancer-derived bone metastases.22 A
key step towards the emergence of high-grade, castration-resistant
prostate cancer involves point mutations in androgen receptor.
One such mutation (W741C) results in the reversal of the antago-
nistic effect the antiandrogen drug bicalutamide, whereas other
mutations can lead to the activation of mutant AR in a ligand-inde-
pendent manner.23 Enzalutamide behaves as an antagonist of both
the wild-type and, in contrast to bicalutamide, the W741C mutant
androgen receptor and prevents its translocation into the nucleus,
thereby disrupting an assembly of the functional transcription fac-
tor complex. Despite the remarkable progress in targeting
advanced prostate cancer, however, a large portion of the chemo-
therapeutic repertoire remains to be represented by relatively
non-speciﬁc cytotoxins.24 Py–Im polyamide 1 targets the consen-
sus ARE and should also prevent binding of both wild-type and
W741C mutant androgen receptors to DNA. Such an approach
could, in principle, be immune to further mutations in AR.
The comparison of Py–Im polyamide tissue concentrations to
those of other C-14 labeled DNA binding drugs enable the contex-
tualization of the pK proﬁle of 1. Quantitative in vivo data from C-
14 labeling experiments exist for the clinically approved chemo-
therapeutic doxorubicin, which warrants an explicit comparison
to the present investigation. A subcutaneous xenograft model
was conducted for the MCF7 cell line, with doxorubicin injected
intraperitoneally at 1.6 mg/kg.17 This is close to the quantities of
the C-14 labeled Py–Im polyamides administered in the present
study (20 nmol of 1 injected into an animal with a typical weight
of 30 g corresponds to a 0.93 mg/kg dose). The authors of the doxo-
rubicin study reported tumor localization values of about 1 mg/kg
for their xenografts, monitored for up to 24 h after a single injec-
tion. We measured values of about 1.5 mg/kg for the compounds
1–3 at the 24 h timepoint. This can be considered encouraging,
given that doxorubicin is a clinically approved chemotherapeutic.
A drastic difference is noted for the liver-associated compound
values. Whereas the liver levels of compound 1 did not change
markedly between the 4 and 24 h time point, and were consider-
ably lower than the tumor levels at both time points (2-fold and
1.5-fold, respectively), doxorubicin was found to localize to the
liver at levels some 2-fold higher than those measured for the
MCF7 xenografts initially (2 h timepoint), but then to clear rapidly.
Given the chemical reactivity of doxorubicin, metabolic processing
appears likely, and may in fact give rise to toxic intermediates that
are devoid of the C-14 label. In our study, Py–Im polyamide 1 was
found to clear slowly (over the course of 7 days) and at comparable
rates from both the LNCaP xenografts and the host organs assessed,
thus suggesting non-speciﬁc clearance rather than metabolic pro-
cessing. This interpretation is further supported by the data
obtained with the differentially labeled compound 2, which
yielded values comparable to those of 1 at the 24 h timepoint, thus
underscoring the stability of this Py–Im polyamide in vivo.
Some twofold accumulation of 1 was observed upon repeated
injection in both the tumor and the animal organs assessed.
Whereas the tumor accumulation is an asset of the molecule, the
organ retention prompts a note of caution. Advanced delivery
strategies, such as nanoparticle formulations or tumor-homing
moieties, could be employed to reduce host organ accumulation.25
Amelioration of doxorubicin toxicity in a liposomal (cardiolipin)
formulation has been previously demonstrated to result in analtered organ distribution, with consistently lower tissue com-
pound levels measured for the cardiolipin formulation.26
Comparison of Py–Im polyamide 1 with the closely related ana-
log 3 reveals that the acetylated compound 1 exhibits some 2-fold
reduced host tissue levels without affecting the concentration in
the LNCaP xenografts, which is clearly an advance for translation
aspects. This allows to rationalize an aspect of the preceding study,
namely that a single injection of the non-radioactive version of 3,
but not 1, at 10 mg/kg resulted in liver toxicity.10 Overall, the study
demonstrates the value of subtle molecular variation in improving
molecular in vivo properties of drug candidates.
B. Mechanistic aspects: We measured a mean tumor concentra-
tion of 3.49 mg/kg (2.50 lM) in the multiple injection experiment
(Fig. 5), which is remarkably close to the IC50 value measured for
the non-radioactive version of 1 in LNCaP cell culture (2.1 lM).10
This is not inconsistent with direct cytotoxic action of the com-
pound upon the tumor, as opposed to an indirect effect, which could
stem from disrupting the nutrient supply due to systemic host tox-
icity, or from the interference with host growth hormone produc-
tion (e.g., testosterone). The question that remains is whether the
compound exerts its cytotoxic effects directly on the xenografted
LNCaP cells or does so by disrupting the tumor microenvironment.
These two scenarios would lead to the same functional readout,
namely attenuation of tumor proliferation. They therefore cannot
be readily distinguished with the C-14 labeling method, because
averaged whole-tumor compound levels are obtained.
It should be kept in mind that, although the in vivo tumor-levels
measured for 1 are close to the IC50 measured in cell culture for the
non-radioactive version of the compound, an explicit comparison
between a cell culture study and an in vivo experiment is a prob-
lematic one. In a xenograft experiment, a complex and dynamic
interface is formed between the grafted (human) cell line and the
host animal. The interface encompasses angiogenesis, inﬁltration
by various immune cells (even the heavily immunosuppressed
NSGmice still possess some functional aspects of the innate immu-
nity wing) and hormone signaling, inter alia. It is further compli-
cated by the fact that in cell culture, the compound exposure is
invariant over the experimental time frame, while an oscillatory
proﬁle is expected in tumors due to clearance. Correspondingly,
the concentration of 2.5 lM, which was measured in the accumu-
lation experiment 24 h after administration of Py–Im polyamide, is
likely to somewhat underestimate the peak tumor levels that are
reached. Finally, xenografts are heterogenous in nature, and as
such spatial variance of compound levels within an individual
tumor can be expected. Genetically engineered tumor models
(e.g., the TRAMP mouse) tend to recapitulate the host-tumor inter-
face more accurately than xenograft models, and may hence be of
value in shedding light onto mechanism of action of Py–Im polya-
mides in future in vivo studies.274. Conclusion
Three C-14 radioactively labeled Py–Im polyamides were syn-
thesized and their levels quantitated in subcutaneous LNCaP xeno-
grafts following intraperitoneal administration. The measured
compound levels were compared with representative host samples
(kidney, liver and lung). An up to 12-fold preferential tumor local-
ization (compared to lung) was measured for the Py–Im polyamide
1 and its differentially labeled chemical equivalent 2, but not for
the charged analog 3. This demonstrates the value of small mole-
cule modiﬁcations to improve therapeutic index of drug candi-
dates, and is in line with preceding toxicity studies.10 Upon
repeated administration (three injections over 7 days), compound
1 exhibited some twofold accumulation in all tissues examined.
Comparison with 2 suggested that metabolic processing does not
J. A. Raskatov et al. / Bioorg. Med. Chem. 22 (2014) 4371–4375 4375play a signiﬁcant role over the time period probed. The tumor lev-
els of 1 that were achieved in the accumulation experiment are
comparable to the IC50 measured for the LNCaP cell line in culture.
4.1. Materials and methods
4.1.1. Synthesis of radioactively labeled compounds
The core for the Py–Im polyamides 1–3 was synthesized on
resin, following previously reported procedures.28 Radioactive
building blocks were obtained from ARC and conjugated to Py–
Im polyamide intermediates following standard protocols (Sup-
porting information, Fig. SI2). All compounds were quantitated
by liquid scintillation counting prior to injection, employing the
activity constants of 55 mCi/mmol (isophthalic acid) and 25 mCi/
mmol (acetate), as provided by the vendor of radioactive materials.
All spectra were quench-corrected using a standard curve that was
produced employing Beckman C-14 standards and deﬁned quanti-
ties of nitromethane as the quenching agent (Supporting informa-
tion, Fig. SI3). All compounds were conﬁrmed single peaks (purity
>99%) by analytical HPLC and co-eluted with the corresponding
non-radiolabeled materials as additional quality control.
4.1.2. Cell culture and in vivo experimentation
The LNCaP cell line was obtained from ATCC and cultured fol-
lowing the vendor’s recommendations. Cells were not allowed to
exceed passage number 25. Engraftment was only performed,
where cell viability exceeded 90% by trypan blue staining. Male
NSG mice were obtained from JAX and housed in a level A animal
facility in accordance with IACUC regulations. Cells were grafted
subcutaneously (ﬂank) in 200 lL of a 1:1 mixture cell culture
media and matrigel at 2.5 M per inoculation. Tumor growth was
monitored weekly. Animals were administered the radioactively
labeled compound 4–8 weeks after engraftment in a speciﬁcally
dedicated fume hood that was set up for C-14 radioexperimenta-
tion. Where exposure exceeded 24 h, animals were transferred to
an isolated facility with regulated temperature, humidity and a
light-dark cycle, and removed for terminal procedures as needed.
In order to ensure optimal hydration of animals, gelpacks were
supplied once in three days in addition to the standard water bot-
tles. All animals were housed in disposable cages, which were
destroyed at the end of the experiment, following established
radiosafety protocols. Animals were euthanized by CO2 asphyxia-
tion at gas pressures of 2–3 atm. Tumors of varying sizes were
evaluated, the majority falling between 25 and 200 mg upon exci-
sion, although occasional outliers in both directions were present.
No correlation was noted between tumor size and compound accu-
mulation (Supporting information, Fig. SI4).
4.1.3. Tissue solubilization and quantitation of Py–Im
polyamide levels
Tumors, kidneys, livers and lungs were excised, rinsed with PBS
and the residual washing liquid absorbed on paper towels. Single
samples typically did not exceed 300 mg per solubilization exper-
iment. Individual samples were placed into scintillation vials and
1 mL SOLVABLE (Perkin Elmer) added. Vials were subsequently
placed into an incubator (+55 C) for a minimal incubation period
of 12 h. Samples were removed from the incubator, allowed to cool
to ambient temperature and 2  200 lL of an aqueous hydrogen
peroxide solution added (30% w/w, Sigma–Aldrich). Once there
was no further visible evolution of gas, the samples were placed
back into the incubator for an additional hour. They were subse-
quently allowed to cool back down to ambient temperature and
10 mL of the scintillation ﬂuid HIONIC-FLUOR (Perkin Elmer)added per vial. Scintillation counting was performed on a Beckman
Coulter LS6500 Multi-Purpose Scintillation Counter. All values
were quench-corrected using IC# in conjunction with the quench
curve (Supporting information, Fig. SI3) and normalized for initial
organ weight.
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